OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Yahoo Finance · Oct 10, 2025 · Chemomab Therapeutics Ltd DRC (CMMB)
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
Not investment advice. Cached headline, not a full reprint.